Please assess the completion status of the following clinical trial:

Trial Title: PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older~* Initiated on VV ECMO for acute respiratory distress syndrome~* Receiving piperacillin/tazobactam~Exclusion Criteria:~* Pregnancy~* Massive blood transfusion (10 units or more of of PRBC) within a 24-hour period~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VV ECMO (Type: None): Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).